EDTUTC-4 New YorkLog in Sign up

RVMDW
Revolution Medicines, Inc. Warrant
stockNASDAQWarrant

At CloseOct 2, 2026 3:59:59 PM EDT

11.53USD-0.603%(-0.07)13,699

RVMDW News

Day breaks

11:29 AM EDTAmgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ·

The Motley Fool

05:50 PM EDTNew England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer ·

GlobeNewswire Inc.

07:07 AM EDTRevolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? ·

The Motley Fool

06:17 PM EDTOnco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib) ·

GlobeNewswire Inc.

12:59 PM EDTU.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer ·

GlobeNewswire Inc.

04:51 PM EDTERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS ·

GlobeNewswire Inc.

03:47 PM EDTERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights ·

GlobeNewswire Inc.

03:44 PM EDTERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman ·

GlobeNewswire Inc.

10:27 PM EDTErasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline ·

GlobeNewswire Inc.